ArticleLeukemia & lymphoma2021

Does the conventional cytogenetic risk profile still matter for prediction of venetoclax based treatment outcomes in AML?

Jan Philipp Bewersdorf et al.PubMed ↗Publisher ↗

No numbers read from the abstract.